---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-028372"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:54:10.201991+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Heron Q4 net income $3.6M; FY2024 rev $144.2M (+14%); guides 2025 rev $153-163M

## Summary
- Q4 2024 GAAP net income of $3.6M; full-year 2024 adjusted EBITDA of $8.6M.
- Full-year 2024 net revenue $144.2M (+14% YoY); Acute Care revenue up 57%, Oncology up 6%.
- 2025 guidance: net revenue $153-163M, adjusted EBITDA $0-8M.
- U.S. District Court upheld CINVANTI patents against Fresenius Kabi; patents expire 2035.
- Cash and investments $59.3M; ZYNRELEF VAN launched Dec 2024; Crosslink partnership.

## SEC filing metadata
- accession: 0000950170-25-028372
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017025028372/0000950170-25-028372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017025028372/hrtx-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-028372
- JSON: https://secwatch.observer/filing/0000950170-25-028372.json
- Plain text: https://secwatch.observer/filing/0000950170-25-028372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.